In patients with cholangiocarcinoma who qualify for HAIP therapy, would you recommend treating with chemotherapy and immunotherapy?

While HAIP is considered promising (again - 20 years later), no appropriate phase III trial has shown benefit in any diagnosis. Since phase III trials support immunotherapy, that is preferred.

Thank you for the question. I agree that the HAIP can be an effective option for carefully selected patients ineligible for resection in the hands of experts experienced with HAIP- and has offered improvements in PFS & OS. However, to date, published data has only been in combination with cytotoxic chemotherapy (e.g. gemcitabine + oxaliplatin) without a checkpoint inhibitor. I would not give these concurrently outside of a clinical trial and in the absence of prospective data. This is bearing in...

Based on the concept that hepatic metastases derive most of their blood supply from the hepatic artery as opposed to venous system hepatic arterial infusion (HAI) has been evaluated in the past for mostly colorectal cancer patients with hepatic metastases. (Copur et al., PMID 11331319, Kemeny et al., PMID 16505413). Over the past two decades, HAI chemotherapy in colorectal cancer has come a long way through improved surgical techniques and the discovery of new therapeutic agents. The future of H...